Tarnished HALO For Targacept/AstraZeneca Schizophrenia Drug
This article was originally published in The Pink Sheet Daily
Executive Summary
Partners halt development of AZD3480 in schizophrenia after Phase II failure, but will wait for ADHD trial before deciding the fate of the compound.